An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease

Launched by ABBVIE · Jun 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called ABBV-951 to see how well it works and how safe it is for adults with advanced Parkinson's disease (PD). Parkinson's disease is a condition that affects movement, causing symptoms like tremors and stiffness. The trial will include about 250 adults in Japan who have been prescribed ABBV-951 by their doctors. Participants will receive this treatment as part of their regular care and will be monitored for a year to track any changes in their symptoms and any side effects they might experience.

To be eligible for the study, participants need to have a diagnosis of advanced Parkinson's disease and must be prescribed ABBV-951 as part of their treatment. They should also be able to provide consent to participate. Participants who have previously used ABBV-951 or are involved in other clinical trials will not be included. Throughout the study, participants can expect to have their usual doctor visits, which may take place in person or online, with no extra burden added to their routine.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with advanced Parkinson's disease (aPD).
• • Prescribed ABBV-951 as physicians' decision according to the approved label for treatment of aPD.
• • Given informed consent (or by her/his legal representative, if it's a requirement from the participating hospital/clinic) for participating this study.
• Exclusion Criteria:
• • Prior treatment with ABBV-951 for PD.
• • Currently participating in interventional clinical trials.